AGP Executive Report
Last update: 3 hours agoBiotechnology: EU regulators backed an expanded use of Merck’s RSV treatment for high-risk children, with a final decision expected within two months across the EU, Liechtenstein, Iceland and Norway. Cancer Research: The EMA also recommended belzutifan plus lenvatinib for advanced kidney cancer after prior immunotherapy; the European Commission will decide on approval. Digital Security: Austria’s MACO Group is taking a majority stake in fingerprint-access maker ekey, which has operations in Liechtenstein. Ekey’s brand, products and Linz research and production base are set to remain. Climate and Energy: Liechtenstein joined countries backing a COP31 pledge to raise electricity’s share of global energy use to 35% by 2035, though the pledge does not specify how that power should be generated. Banking Technology: A study of Swiss and Liechtenstein banks found 65% expect to keep their core banking systems for at least a decade, despite widespread criticism of usability and slow innovation. Youth and STEM: Switzerland’s National Future Day drew thousands of children to explore careers, including fields where their gender is under-represented.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
